Trial reportClinical research in cardiology : official journal of the German Cardiac Society2010
Telmisartan improves absolute walking distance and endothelial function in patients with peripheral artery disease.
Trial report in Clinical research in cardiology : official journal of the German Cardiac Society, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Effects of Angiotensin-Converting Enzyme Inhibitors on Arterial Stiffness: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Cardiovascular therapeutics · 2020Pooled it
- Pooled it
- Treatment of hypertension in peripheral arterial disease.The Cochrane database of systematic reviews · 2013Pooled it
- Trial
- Chronic protection against ischemia and reperfusion-induced endothelial dysfunction during therapy with different organic nitrates.Clinical research in cardiology : official journal of the German Cardiac Society · 2012Trial
- Contemporary Medical Management of Peripheral Arterial Disease.Cardiovascular drugs and therapy · 2025Review
- Review
- Update on the pathophysiology and medical treatment of peripheral artery disease.Nature reviews. Cardiology · 2022Review
- Renin-Angiotensin System Blockade Is Associated with Exercise Capacity, Sympathetic Activity, and Endothelial Function in Patients with Chronic Kidney Disease.Kidney & blood pressure research · 2022Article
- Role of Blood Stasis Syndrome of Kampo Medicine in the Early Pathogenic Stage of Atherosclerosis: A Retrospective Cross-Sectional Study.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Article
- Angiotensin receptor blockers & endothelial dysfunction: Possible correlation & therapeutic implications.The Indian journal of medical research · 2016Review
- Clinical Significance of Endothelial Dysfunction in Essential Hypertension.Current hypertension reports · 2015Review
- Candesartan restores pressure-induced vasodilation and prevents skin pressure ulcer formation in diabetic mice.Cardiovascular diabetology · 2015Article
- The renin-angiotensin system and prevention of age-related functional decline: where are we now?Age (Dordrecht, Netherlands) · 2015Review
- Therapeutic approach in the improvement of endothelial dysfunction: the current state of the art.BioMed research international · 2013Review
- Automated photoplethysmography-based determination of ankle-brachial index: a validation study against Doppler sonography.Clinical research in cardiology : official journal of the German Cardiac Society · 2012Article
- Effect of Angiotensin-converting enzyme inhibitors and Angiotensin receptor antagonists in atherosclerosis prevention.Current cardiology reports · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeripheral artery disease (PAD) is associated with high cardiovascular mortality and a poor quality of life. The AT1-receptor blocker telmisartan has been shown to have pleiotropic effects and it may also improve endothelial function. The aim of this study was to analyze the effects of telmisartan on absolute walking distance (WD) and endothelial function in patients with PAD.
methodsIn a single centre, single-blinded, prospective study, 36 patients with PAD at stage Fontaine II or higher and mild to moderate arterial hypertension were treated with telmisartan 40/80 mg once daily or placebo for 12 months. Primary endpoint was the improvement of the absolute treadmill WD. Flow-mediated vasodilation (FMD), carotid intima-media thickness (IMT), ankle-brachial index (ABI) and disease-related quality of life (DRQL) were examined as well.
resultsAfter 12 months, maximum WD increased by 26% in the telmisartan group (P < 0.001). However, in the placebo group it was comparable to baseline. FMD rose by 40% in the telmisartan group while it deteriorated in the placebo group (P < 0.001). IMT and ABI were comparable in both groups at baseline and did not change considerably after 12 months. In non-diabetic patients (72.2%), the ABI did not change in the placebo group, whereas it increased by 11% in the telmisartan group (P < 0.001). While the DRQL remained stable in the telmisartan group, placebo treatment was associated with a marked deterioration (P < 0.01).
conclusionTelmisartan improves WD and endothelial function, the ABI in non-diabetic patients and it may prevent further loss of quality of life in patients with advanced PAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.